by MM360 Staff | Jul 4, 2025 | Publications
Leukemia. 2025 Jul 2. doi: 10.1038/s41375-025-02677-5. Online ahead of print. ABSTRACT The cytogenetic abnormalities translocations t(4;14) and t(14;16) and the deletion of chromosome 17p in newly-diagnosed multiple myeloma are associated with poor disease prognosis...
by MM360 Staff | Jun 27, 2025 | Publications
Cancers (Basel). 2025 Jun 11;17(12):1943. doi: 10.3390/cancers17121943. ABSTRACT Background: Recently, the addition of anti-CD38 monoclonal antibodies (mAbs) to standard first-line triplet regimens, including a proteasome inhibitor (PI), an immunomodulatory drug...
by MM360 Staff | Jun 13, 2025 | Publications
Leuk Lymphoma. 2025 Jun 12:1-11. doi: 10.1080/10428194.2025.2512031. Online ahead of print. ABSTRACT THIS META-ANALYSIS OF EIGHT PHASE 3 RCTS ASSESSED EFFICACY AND SAFETY OF ANTI-CD38 MONOCLONAL ANTIBODIES (MABS) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA...
by MM360 Staff | Jun 6, 2025 | Publications
Clin Lymphoma Myeloma Leuk. 2025 May 14:S2152-2650(25)00159-4. doi: 10.1016/j.clml.2025.05.007. Online ahead of print. ABSTRACT BACKGROUND: The standard treatment for newly diagnosed, transplant-eligible multiple myeloma (NDMM) patients typically involves triplet...
by MM360 Staff | Jun 5, 2025 | Publications
BMC Cancer. 2025 Jun 4;25(1):998. doi: 10.1186/s12885-025-14420-5. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a clonal proliferative disorder of plasma cells with limited curative options. Hepatitis B (HBV) and hepatitis C (HCV) viruses have been implicated in the...
by MM360 Staff | May 28, 2025 | Publications
Front Med (Lausanne). 2025 May 13;12:1575914. doi: 10.3389/fmed.2025.1575914. eCollection 2025. ABSTRACT INTRODUCTION: Multiple myeloma (MM) is a plasma cell malignancy comprising 10% of hematologic cancers, associated with bone marrow dysfunction and organ damage....
